Publications
- The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab2017 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab2016 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study2015 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Novel predictive biomarker RAS: a crossroads or continuing the path taken?2013 | Faculty of Medicine in Pilsen
- The role of cetuximab in the treatment of metastatic colorectal cancer2012 | Faculty of Medicine in Pilsen
- Metastatic colorectal cancer and target EGFR inhibition with cetuximab2012 | Faculty of Medicine in Pilsen
- Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?2024 | Faculty of Medicine in Pilsen
- Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate2024 | Faculty of Medicine in Pilsen
- Pembrolizumab plus enfortumab vedotin in urothelial cancer2024 | Faculty of Medicine in Pilsen
- Klinická onkologie2023 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine, Second Faculty of Medicine
Loading network view...